Company news
Prokidney Corp. (NASDAQ:PROK) news
Prokidney Corp. news releases on 6ix. Latest, Oct 2, 2026: ProKidney Announces Eight Abstracts Selected for Presentation at the American Society…
Press releases & updates
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
October 1, 2026
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
August 10, 2026
ProKidney Appoints Kenneth Locke as Chief Technical Officer
June 2, 2026
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
May 15, 2026
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
March 24, 2026
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
March 17, 2026
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
November 9, 2025
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
November 5, 2025
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
October 28, 2025
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
October 19, 2025
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
August 26, 2025
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
August 11, 2025
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
July 14, 2025
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
July 8, 2025
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
July 7, 2025
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
June 30, 2025
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
May 11, 2025
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
March 16, 2025
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
November 25, 2024
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
November 11, 2024
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
November 4, 2024
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
October 13, 2024
ProKidney to Participate in the UBS Virtual Organ Restoration Day
October 8, 2024
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
September 2, 2024
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
August 8, 2024
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters Option
June 18, 2024
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
June 16, 2024
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
June 10, 2024
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
June 9, 2024
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
June 9, 2024
ProKidney to Participate in the Jefferies Global Healthcare Conference
May 28, 2024
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
May 20, 2024
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
May 9, 2024
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
March 24, 2024
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
March 20, 2024
ProKidney to Participate in Jefferies Biotech on the Bay Summit
February 28, 2024
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
November 29, 2023
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
November 20, 2023
ProKidney Reports Third Quarter Financial Results
November 13, 2023
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
November 12, 2023
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
October 29, 2023
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
September 4, 2023
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
August 9, 2023
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
July 17, 2023
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
July 16, 2023
ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
June 12, 2023
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
May 31, 2023